191 related articles for article (PubMed ID: 32340874)
1. Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications.
Schneider B; Glass Ä; Jagdmann S; Hühns M; Claus J; Zettl H; Dräger DL; Maruschke M; Hakenberg OW; Erbersdobler A; Zimpfer A
Clin Genitourin Cancer; 2020 Oct; 18(5):e563-e572. PubMed ID: 32340874
[TBL] [Abstract][Full Text] [Related]
2. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
[TBL] [Abstract][Full Text] [Related]
3. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of microsatellite instability in endometroid carcinoma with deficient mismatch repair].
Zhang YH; Wu HW; Wang J; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2021 May; 50(5):470-475. PubMed ID: 33915653
[No Abstract] [Full Text] [Related]
7. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
[TBL] [Abstract][Full Text] [Related]
8. Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study.
Calandrella ML; Francesconi S; Caprera C; Mosillo C; Caserta C; Giannarelli D; Corsi M; Macrini S; Guida A; Ascani S; Bracarda S
BMC Cancer; 2022 Feb; 22(1):168. PubMed ID: 35164713
[TBL] [Abstract][Full Text] [Related]
9. Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort.
Kullmann F; Strissel PL; Strick R; Stoehr R; Eckstein M; Bertz S; Wullich B; Sikic D; Wach S; Taubert H; Olbert P; Heers H; Lara MF; Macias ML; Matas-Rico E; Lozano MJ; Prieto D; Hierro I; van Doeveren T; Bieche I; Masliah-Planchon J; Beaurepere R; Boormans JL; Allory Y; Herrera-Imbroda B; Hartmann A; Weyerer V
J Clin Pathol; 2023 Feb; 76(2):126-132. PubMed ID: 34583948
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
11. Lynch syndrome-associated upper tract urothelial carcinoma frequently occurs in patients older than 60 years: an opportunity to revisit urology clinical guidelines.
Pivovarcikova K; Pitra T; Alaghehbandan R; Buchova K; Steiner P; Hajkova V; Ptakova N; Subrt I; Skopal J; Svajdler P; Farcas M; Slisarenko M; Michalova K; Strakova Peterikova A; Hora M; Michal M; Daum O; Svajdler M; Hes O
Virchows Arch; 2023 Oct; 483(4):517-526. PubMed ID: 37612527
[TBL] [Abstract][Full Text] [Related]
12. [Mismatch repair protein expression of colorectal cancer: a retrospective analysis of 3 428 cases].
Liu Y; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Zang FL; Qiu ZQ; Sun BC; Sun Y
Zhonghua Bing Li Xue Za Zhi; 2021 Apr; 50(4):369-375. PubMed ID: 33831997
[No Abstract] [Full Text] [Related]
13. [Should we systematically screen for Lynch syndrome in patients with upper urinary tract carcinoma?].
Olagui GS; Pignot G; Rouquette A; Vieillefond A; Amsellem-Ouazana D; de Longchamps NB; Radenen B; Zerbib M; Terris B
Bull Cancer; 2014 Feb; 101(2):144-50. PubMed ID: 24556207
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II.
Tanabe K; Nakanishi Y; Okubo N; Matsumoto S; Umino Y; Kataoka M; Yajima S; Yoshida T; Miyazaki S; Kuwata T; Ishii G; Watanabe R; Masuda H
BMC Cancer; 2023 Oct; 23(1):940. PubMed ID: 37798659
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
16. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
17. High homogeneity of MMR deficiency in ovarian cancer.
Fraune C; Rosebrock J; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Clauditz TS; Wilczak W; Sauter G; Steurer S; Burandt E
Gynecol Oncol; 2020 Mar; 156(3):669-675. PubMed ID: 31924330
[TBL] [Abstract][Full Text] [Related]
18. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
19. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma.
Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
[TBL] [Abstract][Full Text] [Related]
20. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
